论文部分内容阅读
目的探讨克林澳治疗短暂性脑缺血发作(TIA)的临床疗效。方法将72例TIA患者随机分为治疗组、对照组各36例,治疗组采用克林澳治疗,对照组采用复方丹参治疗,观察临床疗效和药物不良反应。结果治疗组总有效率97.2%,明显优于对照组86.2%(P<0.01),24hTIA发作控制率在72.2%,明显优于对照组52.8%(P<0.01)。无明显不良反应。结论克林澳是治疗TIA的一种有效新药,建议临床推广应用。
Objective To investigate the clinical efficacy of Kelin O in the treatment of transient ischemic attack (TIA). Methods Seventy-two patients with TIA were randomly divided into treatment group and control group with 36 cases each. The treatment group was treated with Kelin O and the control group was treated with compound Salvia miltiorrhiza. Clinical efficacy and adverse drug reactions were observed. Results The total effective rate of the treatment group was 97.2%, which was significantly better than that of the control group (86.2%, P <0.01). The control rate of 24hTIA onset was 72.2%, which was significantly better than that of the control group (52.8%, P <0.01). No obvious adverse reactions. Conclusion Kelin O is an effective new drug for the treatment of TIA and is recommended for clinical application.